Rege Nephro secures $10.6M financing
Analysis based on 7 articles · First reported Jul 21, 2026 · Last updated Jul 21, 2026
The financing provides Rege Nephro with capital to advance its pipeline, potentially increasing its valuation ahead of a Series C round. Positive sentiment for the biotech sector, though the amount is modest relative to industry standards.
Rege Nephro Co., Ltd., a clinical-stage biotechnology company based in Kyoto, Japan, announced the closing of a financing round totaling approximately US$10.6 million through the issuance of J-KISS share acquisition rights. The proceeds will support commercialization activities for RN-014, its lead candidate for autosomal dominant polycystic kidney disease (ADPKD), advance its iPS cell-derived regenerative medicine program RN-032, and fund continued R&D. The company recently reached Last Patient Last Visit in its Phase 2a clinical trial for RN-014 and completed process development for RN-032. The financing is intended to support growth through its anticipated Series C financing and beyond. Investors include JAFCO Group, MUFG, SPARX Asset Management, and others.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard